EVE Health Group (ASX:EVE): FY26 Results and Pharmaceutical Development Progress

Aditi Sarkar

26 October 2026 11:31 PM AEDT

EVE Health Group (ASX:EVE): FY26 Results and Pharmaceutical Development Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EVE Health Group (ASX:EVE) reported FY26 revenue of approximately AUD 1.15mn.
The FY26 net loss was approximately AUD 1.89mn, compared with AUD 1.58mn in FY25.
The company advanced its Dyspro women’s-health and Libbo men’s-health programs during 2026.
An April 2026 management change appointed Ben Rohr as chief executive officer.

EVE Health Group Limited develops pharmaceutical products and operates a consumer wellness business, with a focus on women’s and men’s health through its Dyspro and Libbo programs. The group’s FY26 reporting reflected its transition toward product development and commercial activity, alongside continuing operating losses. On 26 October 2026, EVE Health Group (ASX:EVE) was quoted at AUD 0.011 in the market session. Recent company disclosures also outlined management changes and clinical development work on Libbo.

Company Business

EVE Health Group (ASX:EVE) operates through pharmaceutical development activities associated with Nextract and branded wellness products associated with Meluka. Its pharmaceutical portfolio includes Dyspro, a cannabinoid-based pastille under development for menstrual pain and endometriosis-related symptoms, and Libbo, an oral dissolving film developed for erectile dysfunction.

The company has also developed digital information and patient-engagement channels focused on women’s and men’s health. Meluka’s consumer offering includes gut-health and related wellness products.

Recent Development

In April 2026, EVE Health Group (ASX:EVE) appointed Ben Rohr as chief executive officer after his involvement in operational planning and the integration of Nextract. Damian Wood moved from the chief executive role, with a planned focus on regulatory strategy, clinical development and medical affairs.

During June 2026, the company announced the initiation of a pilot clinical study involving its Libbo oral dissolving film. The study represented a development step for the men’s-health program, with subsequent decisions subject to the study findings and applicable regulatory pathways. The company continued to identify Dyspro and Libbo as its principal proprietary pharmaceutical products in its 2026 communications.

EVE Health Group (ASX:EVE) also issued its FY26 annual report in August and made a shareholder meeting notice available in October.

Financial Performance and Sector Context

For the year ended 30 June 2026, EVE Health Group (ASX:EVE) recorded revenue of approximately AUD 1.15mn, compared with approximately AUD 1.73mn in FY25, a reduction of about 33.5% YoY. Its reported net loss increased to approximately AUD 1.89mn from AUD 1.58mn.

The company’s operating cash outflows and access to additional capital remain important considerations as it advances product development. Pharmaceutical commercialisation entails formulation controls, manufacturing arrangements, regulatory requirements and relationships with prescribers and distributors.

Risks to Consider

EVE Health Group (ASX:EVE) faces uncertainty over product development, clinical findings, manufacturing arrangements, regulatory processes and the pace of customer adoption. Expenses may precede revenue, and further investment in development or commercial infrastructure could add pressure to cash flows. Equity capital raising, if undertaken, may dilute existing shareholdings. Its smaller revenue base also increases sensitivity to changes in operating costs and sales volumes.

What to Watch Next

For EVE Health Group (ASX:EVE), subsequent milestones include updates on the Libbo pilot study, progress with Dyspro and any changes to manufacturing, distribution or prescribing arrangements. Financial reporting will show whether product development expenditure and customer receipts move in line with the company’s plans. Further governance disclosures and quarterly cash-flow statements will help clarify its resources and operating priorities.

Key Insights

EVE Health Group’s FY26 results show reduced revenue and a larger net loss alongside continuing development of its pharmaceutical portfolio. The appointment of a new chief executive and the Libbo pilot study were key 2026 developments. Future assessment centres on clinical and regulatory progress, product availability, commercial sales and the company’s capacity to fund ongoing operations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.